The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden

hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0000883975	STEMCELLS	SINC	Corporation
Name of Issuer	CYTOTHER	APEUTICS INC/DE	Limited Partnership
Microbot Medical Inc.			Limited Liability Company
Jurisdiction of Incorporation	/Organization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organ	ization		Other (Specify)
Over Five Years Ago			
Within Last Five Years	(Specify Year)		
Yet to Be Formed			
2. Principal Place of Busin	ess and Contact Information		
Name of Issuer			
Microbot Medical Inc.			
Street Address 1		Street Address 2	
288 GROVE STREET		SUITE 388	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
BRAINTREE	MASSACHUSETTS	02184	781-875-3605
3. Related Persons			
Last Name	First Name		Middle Name
Gadot	Harel		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Co	ountry	ZIP/PostalCode
Braintree	MASSACHUSETT		02184
Relationship: Executive	e Officer Director Promot	er	
Clarification of Response (if	Necessary):		
Last Name	First Name		Middle Name
Sharon	Simon		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Co	ountry	ZIP/PostalCode
Braintree	MASSACHUSETT	rs .	02184
Relationship: Executive	e Officer Director Promot	er	
Clarification of Response (if	Necessary):		
Last Name	First Name		Middle Name
Diaz-Cartelle	Juan		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Co	ountry	ZIP/PostalCode
Braintree	MASSACHUSETT	'S	02184
Relationship: Executive	e Officer Director Promot	er	
Clarification of Response (if	Necessary):		

Last Name	First Name	Middle Name	
Vaknin	Rachel		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
	fficer Director Promoter		
Clarification of Response (if Ne			
-			
Last Name	First Name	Middle Name	
Madden	Martin	J.	
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
Relationship: Executive Of	fficer 📝 Director 🔲 Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name	Middle Name	
Burell	Scott	madio Hamo	
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
		710/04-10-4-	
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
Relationship: Executive Of	fficer 🚺 Director 🔲 Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name	Middle Name	
Stockburger	Aileen		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
Relationship: Executive Of	fficer Director Promoter		
Clarification of Response (if Ne	cessary):		
	E. I.V.	AP III AI	
Last Name	First Name	Middle Name	
Bornstein	Yoseph		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
Relationship: Executive Of	fficer 🚺 Director 🔲 Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name	Middle Name	
Laxminarain	Prattipati		
Street Address 1	Street Address 2		
288 Grove Street	Suite 388		
City	State/Province/Country	ZIP/PostalCode	
Braintree	MASSACHUSETTS	02184	
	fficer Director Promoter	02101	
Clarification of Response (if Ne			
Last Name	First Name	Middle Name	
Wenderow	Tal	madio Hamo	
Street Address 1	Street Address 2		
i	01.00t / tadi 000 Z		

288 Grove Street	Suite 388			
City State/Province/Country		ZIP/PostalCode		
Braintree	MASSACHUSETTS	02184		
Relationship: Executive Officer D	irector Promoter			
Clarification of Response (if Necessary):				
,				
4. Industry Group				
Agriculture	Health Care			
Banking & Financial Services		Retailing		
	Biotechnology	Restaurants		
Commercial Banking	Health Insurance	Technology		
Insurance	Hospitals & Physicians	Computers		
Investing Investing	Pharmaceuticals	Telecommunications		
Pooled Investment Fund				
	Other Health Care	Other Technology		
Is the issuer registered as an investment company under	Manufacturing	Travel		
the Investment Company	Real Estate	Airlines & Airports		
Act of 1940?	Commercial	Lodging & Conventions		
Yes No	Construction	Tourism & Travel Services		
Other Banking & Financial Servi				
Business Services	TETTO & Titlance	Other Travel		
Energy	Residential	Other		
Coal Mining	Other Real Estate			
Electric Utilities				
Energy Conservation				
Environmental Services				
Oil & Gas				
Other Energy				
5. Issuer Size				
Davis Davis Davis	A company to Nick A cont Value	D		
Revenue Range OR No Revenues	Aggregate Net Asset Value			
\$1 - \$1,000,000	No Aggregate Net Asse	et value		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,0	00		
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000			
\$25,000,001 -				
\$100,000,000	\$50,000,001 - \$100,000	0,000		
Over \$100,000,000	Over \$100,000,000			
Decline to Disclose	Decline to Disclose			
Not Applicable	Not Applicable			
6. Federal Exemption(s) and Exclusion(s	s) Claimed (select all that annly)			
on todard Exampliants, and Exampliants, ordinated todards an indicapping				
	Investment Company	Act Section 3(c)		
Duta 504/b)/4) (5 at (i) (ii) as (iii))	Section 3(c)(1)	Section 3(c)(9)		
Rule 504(b)(1) (not (i), (ii) or (iii))				
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)		
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)		
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)		
Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)		
Securities Act Section 4(a)(5)				
	Section 3(c)(6)	Section 3(c)(14)		
	Section 3(c)(7)			
7. Type of Filing				
New Notice Date of First Sale 2024-06-03 First Sale Yet to Occur				
Amendment				
8. Duration of Offering				

Does the Issuer intend this offering to last more than one year?	Yes V No	
9. Type(s) of Securities Offered (select all that apply)		
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant of Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities or Other Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combir merger, acquisition or exchange offer?	nation transaction, such as a Yes No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USI	D	
12. Sales Compensation		
Recipient H.C. Wainwright & Co. (Associated) Broker or Dealer None None Street Address 1 430 Park Avenue	Recipient CRD Number None 000000375 (Associated) Broker or Dealer CRD Number None None Street Address 2 4th Floor	
City New York State(s) of Solicitation (select all that apply) Check "All States" or check individual States NEW YORK NEW YORK	State/Province/Country NEW YORK Foreign/non-US	ZIP/Postal Code 10022
13. Offering and Sales Amounts		
Total Offering Amount \$1,762,502 USD or Indefinite Total Amount Sold \$1,762,502 USD Total Remaining to be Sold \$0 USD or Indefinite Clarification of Response (if Necessary): Gross proceeds received from registered offering of common stock and		ign investor. Gross
proceeds if the warrants are exercised (excluding those issued to the for	teign investor) is \$5,325,005.	
enter the number of such non-accredited investors who alr	or may be sold to persons who do not qualify as accredited	3
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finder an estimate and check the box next to the amount.	rs fees expenses, if any. If the amount of an expenditure is no	ot known, provide
Sales Commissions \$164,500 USD Estimate Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
The placement agent received an aggregate cash fee equal to 7.0% of the designees received warrants to purchase 78,333 common shares exercise		ceeds, and its

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

16. Use of Proceeds

\$0 USD	Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Microbot Medical Inc.	/s/ Harel Gadot	Harel Gadot	Chief Executive Officer	2024-06-20

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D. States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.